Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis S.A. (NASDAQ: CLLS) announced the filing of a prospectus supplement with the SEC related to an At-The-Market (ATM) program, allowing sales of American Depositary Shares (ADS) up to $125 million. The program aims to fund research, development, and manufacturing in the biotechnology space. Notably, this could lead to a dilution of approximately 29.74% based on existing share capital. Jefferies LLC will act as the sales agent, and the program is effective until June 2, 2023.
Cellectis, a clinical-stage biopharmaceutical company, focuses on CAR-T immunotherapies for oncology, utilizing its proprietary TALEN® gene editing technology. The company reported a total of 43,033,680 shares and 49,098,269 voting rights as of February 28, 2021. Cellectis aims to provide innovative UCART product candidates for cancers such as acute myeloid leukemia and multiple myeloma. Headquartered in Paris, Cellectis is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis reported ongoing enrollment in three Phase 1 dose-escalation trials for r/r B-ALL, r/r AML, and r/r MM, with preliminary results of the BALLI-01 study presented at ASH 2020. The company has partnered with Cytovia Therapeutics to develop TALEN® gene-edited NK cell programs and completed construction of manufacturing facilities in Paris and North Carolina. As of December 31, 2020, Cellectis had a cash position of $274 million, extending its cash runway into late 2022. A conference call is scheduled for March 5, 2021, to discuss year-end results and business updates.
Cellectis (Nasdaq: CLLS) will report its financial results for Q4 and full year 2020 on March 4, 2021, post US market close. A conference call will follow on March 5, at 8:00 AM EST. The company is developing innovative allogeneic CAR-T immunotherapies utilizing its proprietary TALEN® gene editing technology. Cellectis focuses on treating unmet needs in multiple cancers, including AML and B-ALL. The announcement comes amid ongoing advancements in its UCART product candidates and a commitment to delivering actionable therapies.
Cytovia Therapeutics and Cellectis have formed a strategic collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. This partnership could yield up to $760 million in milestones for Cellectis. Cellectis will get single-digit royalties on sales of partnered products. Cytovia is responsible for the clinical development of these therapies, aiming for trials by 2022. The collaboration is anticipated to enhance NK cell therapies' efficacy for various cancers, capitalizing on Cellectis' gene-editing expertise to improve safety and effectiveness.
Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis announced a registered direct offering through its subsidiary Calyxt, securing $15 million by selling 3,750,000 shares at $4.00 each. Cellectis will purchase 1,250,000 shares, raising its ownership stake in Calyxt to 64.7%. The offering, set to close around October 20, 2020, will fund general corporate purposes, including advancing product development and TALEN® technology. H.C. Wainwright & Co. acts as the exclusive placement agent. The shares are offered under an effective SEC registration statement.
Cellectis announced updates on its share capital and voting rights as of September 30, 2020. The total number of shares in the capital reached 42,486,133, while the total voting rights amounted to 47,940,528. Specializing in CAR-T immunotherapies, Cellectis focuses on innovative gene editing technologies to treat various cancers, including acute myeloid leukemia and multiple myeloma. The company’s mission is to provide effective UCART product candidates to address unmet medical needs in oncology.
Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. As of August 31, 2020, the company has 42,486,133 shares outstanding and 47,940,778 voting rights. Their innovative approach leverages TALEN® technology to target a range of cancers including AML, B-ALL, and MM. Headquartered in Paris, Cellectis is publicly traded on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The company aims to meet urgent medical needs in oncology, leveraging over 20 years of gene editing expertise.
Cellectis (Nasdaq: CLLS), a clinical-stage biopharmaceutical company, announced participation in several investor conferences to showcase its advancements in gene-edited CAR T-cell therapies. Notable events include presentations at the Citi Annual BioPharma Conference on September 9, 2020, and the Wells Fargo Healthcare Conference on September 10, 2020. Cellectis focuses on developing innovative treatments for various cancers using proprietary technologies like TALEN® and PulseAgile.
The company's goal is to provide life-saving UCART therapies for unmet cancer treatment needs.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
